Tag
Prolijune Lifesciences Private Limited
2 articles
Mankind Pharma Q2 Net Profit Rises 27% YoY
Board approved Q2 FY27 standalone net profit of ₹581.95 Cr, up 27% YoY, with revenue at ₹3,145.22 Cr.
Approved amalgamation of two wholly-owned subsidiaries, Prolijune Lifesciences and Pavi Buildwell,
Mankind Pharma Q2 Net Profit Up 27% YoY, Approves Subsidiary Amalgamation
Approved unaudited standalone and consolidated financial results for Q2 and H1 FY27, reporting standalone net profit of ₹581.95 crore for the quarter.
Board approved Scheme 1 for amalgamation of wholl